Nordic Pharma partners with Harrow to launch an authorized generic of Maxitrol

Maxitrol and generic equivalents have a total of $20.8 million in annual sales in the US as of January 2025, according to IQVIA data. Image credit: AdobeStock/itchaznong

Nordic Pharma, a subsidiary of Nordic Group BV, has announced a partnership with Harrow to launch an authorized generic of Maxitrol (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension), which treats and relieves bacterial eye infections, according to a news release.¹

"Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace. This product is a great addition to our generic portfolio, providing patients another affordable prescription option," said Thomas Sammler, vice president of Commercial Operations at Nordic Pharma, in the release.

Maxitrol has been the leading corticosteroid/antibiotic combination drop for the treatment of ocular inflammation and bacterial infections for more than 50 years, according to Harrow.² Maxitrol and generic equivalents have a total of $20.8 million in annual sales in the US as of January 2025, according to IQVIA data.¹

The particular anti-infective drug in Maxitrol is active against common bacterial eye pathogens, including Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseeria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens and Streptococci, including Streptococcus pneumoniae.²

“Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation,” Harrow states in Maxitrol’s prescribing information. “They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.”

References:

1. Nordic Group BV through its subsidiary Nordic Pharma, Inc (US), announces launch of authorized generic of Maxitrol (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension). News release. PR Newswire. April 24, 2025. Accessed April 29, 2025. https://www.prnewswire.com/news-releases/nordic-group-bv-through-its-subsidiary-nordic-pharma-inc-us-announces-launch-of-authorized-generic-of-maxitrol-neomycin-and-polymyxin-b-sulfates-and-dexamethasone-ophthalmic-suspension-302436485.html

2. Maxitrol. Harrow. Accessed April 29, 2025. https://maxitrolrx.com/